SEC Form 4Coverage since Jun 2, 2026
$JANX insider trading
Over the last 12 months, Janux Therapeutics insiders reported no purchases and 1 sale totaling $57K across SEC Form 4 filings.
- Bought · 12m
- — 0 events
- Sold · 12m
- $57K 1 event
- Events · 12m
- 1 Form 4 filings, grouped
- Insiders · 12m
- 1 distinct reporters
- 10b5-1 share
- 0% pre-arranged plans
Side
Price · $JANX · 12Mvia TradingView
Top insiders · 12m
Doyle Janeen NoelChief Corp. & Bus. Dev. Ofcr1× · $57K
All insider trades
1 event
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jun 2, 2026 | Doyle Janeen NoelChief Corp. & Bus. Dev. Ofcr · O | ▼ Sale | 4,059 | $14.03 | $57K | -5.1% | — |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $JANX feed.